UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Annals of oncology, 2021-07, Vol.32 (7), p.839-853

2021

Volltextzugriff (PDF)

Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions

Cancer treatment reviews, 2018-03, Vol.64, p.21-29

2018

Volltextzugriff (PDF)

Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients

British journal of cancer, 2017-10, Vol.117 (8), p.1128-1138

2017

Volltextzugriff (PDF)

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR -mutant non-small cell lung cancer: A new era begins

Cancer treatment reviews, 2014-02, Vol.40 (1), p.93-101

2014

Volltextzugriff (PDF)

Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies

Cancer treatment reviews, 2015-01, Vol.41 (1), p.27-34

2015

Volltextzugriff (PDF)

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

The European respiratory journal, 2011-03, Vol.37 (3), p.624-631

2011

Volltextzugriff (PDF)

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

Cancer treatment reviews, 2018-12, Vol.71, p.47-58

2018

Volltextzugriff (PDF)

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

Clinical & translational oncology, 2019-01, Vol.21 (1), p.3-17

2019

Volltextzugriff (PDF)

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Annals of oncology, 2023-05, Vol.34 (5), p.468-476

2023

Volltextzugriff (PDF)

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Annals of oncology, 2018-10, Vol.29 (10), p.2121-2128

2018

Volltextzugriff (PDF)

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

Annals of oncology, 2020-02, Vol.31 (2), p.274-282

2020

Volltextzugriff (PDF)

IBS02.01 Making Sense of Treatment with so Many Options: My Algoritm — A European View

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S90-S90

Reguart, N.

2019

Volltextzugriff (PDF)

Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients

European journal of nuclear medicine and molecular imaging, 2021-10, Vol.48 (11), p.3631-3642

2021

Volltextzugriff (PDF)

The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC

Lung cancer (Amsterdam, Netherlands), 2022-02, Vol.164, p.8-13

2022

Volltextzugriff (PDF)

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

Lung cancer (Amsterdam, Netherlands), 2020-09, Vol.147, p.83-90

2020

Volltextzugriff (PDF)

Beyond EGFR TKI in EGFR -mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome

Cancer treatment reviews, 2014-07, Vol.40 (6), p.723-729

2014

Volltextzugriff (PDF)

miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers

Clinical & translational oncology, 2016-02, Vol.18 (2), p.153-159

2016

Volltextzugriff (PDF)

Sleeve lobectomy after induction chemoradiotherapy

European journal of cardio-thoracic surgery, 2012-05, Vol.41 (5), p.1052-1058

2012

Volltextzugriff (PDF)

Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032

Annals of oncology, 2018-10, Vol.29, p.viii725-viii725

2018

Volltextzugriff (PDF)

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Annals of oncology, 2018-10, Vol.29, p.viii741-viii742

2018

Volltextzugriff (PDF)

Actualisation des données de phase I de recherche de dose et premières données de la phase d’expansion du tarlatamab, un anticorps bispécifique ciblant la protéine DLL3 et engageant les lymphocytes T, dans le cancer bronchique à petites cellules (CBPC)

Revue des maladies respiratoires actualités, 2023-01, Vol.15 (1), p.127-128

2023

Volltextzugriff (PDF)

Successful Oral Desensitization in a Patient With Hypersensitivity Reaction to Crizotinib

Journal of investigational allergology & clinical immunology, 2015-01, Vol.25 (4), p.307-308

2015

Volltextzugriff (PDF)

Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial

Journal francais d'ophtalmologie, 2018-12, Vol.41 (10), p.955-962

2018

Volltextzugriff (PDF)

198TiP Afatinib plus EGF pathway targeting immunization (EGF-PTI) as first line therapy for EGFR mutant NSCLC: The EPICAL study

Journal of thoracic oncology, 2018-04, Vol.13 (4), p.S118-S119

2018

Volltextzugriff (PDF)

1 – 25 von 188

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(186)
Mit Volltextzugriff
(181)

Publikationsform

Artikel
(188)

Sprache

Erscheinungsjahr

n.n

Thema

Humans
(47)
Life Sciences & Biomedicine
(47)
Science & Technology
(47)
Oncology
(35)
Lung Neoplasms - Drug Therapy
(23)
Biological And Medical Sciences
(18)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(18)
Female
(17)
Male
(16)
Medical Sciences
(16)
Lung Neoplasms - Genetics
(15)
Middle Aged
(15)
Aged
(13)
Mutation
(13)
Carcinoma, Non-Small-Cell Lung - Genetics
(12)
Tumors
(12)
Adult
(11)
Pneumology
(11)
Treatment Outcome
(11)
Antineoplastic Agents - Therapeutic Use
(10)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions

Nintedanib selectively inhibits the activation and tumour-promoting effects of fibroblasts from lung adenocarcinoma patients

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR -mutant non-small cell lung cancer: A new era begins

Malignant pleural mesothelioma: New hope in the horizon with novel therapeutic strategies

Brain metastases from lung cancer responding to erlotinib: the importance of EGFR mutation

Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018)

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial

Large scale, prospective screening of EGFR mutations in the blood of advanced NSCLC patients to guide treatment decisions

Association between PD1 mRNA and response to anti-PD1 monotherapy across multiple cancer types

Genome-wide profiling of non-smoking-related lung cancer cells reveals common RB1 rearrangements associated with histopathologic transformation in EGFR-mutant tumors

IBS02.01 Making Sense of Treatment with so Many Options: My Algoritm — A European View

Cell-free DNA concentration and fragment size fraction correlate with FDG PET/CT-derived parameters in NSCLC patients

The EPICAL trial, a phase Ib study combining first line afatinib with anti-EGF vaccination in EGFR-mutant metastatic NSCLC

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group

Beyond EGFR TKI in EGFR -mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome

miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers

Sleeve lobectomy after induction chemoradiotherapy

Nivolumab (N) alone or in combination with ipilimumab (I) in patients (pts) with platinum-pretreated metastatic urothelial carcinoma (mUC), including the nivolumab 1mg/kg + ipilimumab 3mg/kg expansion from CheckMate 032

Results of the GEOMETRY mono-1 phase II study for evaluation of the MET inhibitor capmatinib (INC280) in patients (pts) with METΔex14 mutated advanced non-small cell lung cancer (NSCLC)

Actualisation des données de phase I de recherche de dose et premières données de la phase d’expansion du tarlatamab, un anticorps bispécifique ciblant la protéine DLL3 et engageant les lymphocytes T, dans le cancer bronchique à petites cellules (CBPC)

Successful Oral Desensitization in a Patient With Hypersensitivity Reaction to Crizotinib

Ocular surface adverse events of systemic epidermal growth factor receptor inhibitors (EGFRi): A prospective trial

198TiP Afatinib plus EGF pathway targeting immunization (EGF-PTI) as first line therapy for EGFR mutant NSCLC: The EPICAL study

Suchergebnisse filtern